当前位置: X-MOL 学术Theranostics › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?
Theranostics ( IF 12.4 ) Pub Date : 2017-04-01 , DOI: 10.7150/thno.20284
Steve S. Huang , Warren D.W. Heston

Prostate Specific Membrane Antigen (PSMA) is strongly expressed in prostate cancer. Recently a number of low-molecular-weight inhibitors have demonstrated excellent PSMA targeting activity for both imaging as well as Lutecium-177 radiotherapy in human trials. The paper by Choy et al raises the question of whether we can further increase the effectiveness of PSMA targeted therapy by adding an albumin-binding entity to low-molecular-weight agents

中文翻译:

低分子量PSMA靶向配体是否应该变大并使用白蛋白配体进行PSMA靶向?

前列腺特异性膜抗原(PSMA)在前列腺癌中强烈表达。最近,在人体试验中,许多低分子量抑制剂对成像和Lutecium-177放射疗法均显示出优异的PSMA靶向活性。Choy等人的论文提出了一个问题,即我们是否可以通过在低分子量药物中添加白蛋白结合实体来进一步提高PSMA靶向治疗的有效性
更新日期:2017-07-01
down
wechat
bug